Health.amReferences
1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
2. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years [letter] [see comments]. Lancet. 2000;355:1822.
3. Coleman MP. Trends in breast cancer incidence, survival, and mortality [letter; comment]. Lancet. 2000;356:590-591: discussion 593.
4. Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW. Cancer statistics by race and ethnicity. CA Cancer J Clin. 1998;48:31-48.
5. Soldo BJ, Agree EM. America's Elderly.Washington, DC; Population Reference Bureau, Inc.; 1998.
6. Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW Jr. Cancer statistics by race and ethnicity. CA Cancer J Clin. 1998;48:31-48.
7. Goodwin JS, Hunt WC, Humble CG, Key CR, Samet JM. Cancer treatment protocols. Who gets chosen? Arch Intern Med. 1988;148:2258-2260.
8. Kennedy BJ. Age-related clinical trials of CALGB. Cancer Control. 1995;2:14-16.
9. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials [see comments]. N Engl J Med. 1999;341:2061-2067.
10. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer [see comments]. N Engl J Med. 2000;342:564-571.
11. National Cancer Institute Statistics Review: 1975-1988. NIH pub 91-2789. Bethesda, MD; National Cancer Institute; 1991.
12. Harris JR, Lippman ME, Veronesi U, Willett WC. breast cancer. N Engl J Med. 1992;327:319-328.
13. Rutqvist LE, Wallgren A. Influence of age on outcome in breast carcinoma. Acta Radiol Oncol. 1983;22:289-294.
14. Yancik R, Ries LG, Yates JW. breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer. 1989;63:976-981.
15. Adami HO, Malker B, Meirik O, Persson I, Bergkvist L, Stone B. Age as a prognostic factor in breast cancer. Cancer. 1985;56:898-902.
16. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559-563.
17. Host H, Lund E. Age as a prognostic factor in breast cancer [published erratum appears in Cancer 1986;58(4): 996]. Cancer. 1986;57:2217-2221.
18. Bergman L, Dekker G, van Kerkhoff EH, Peterse HL, van Dongen JA, van Leeuwen FE. Influence of age and comorbidity on treatment choice and survival in elderly patients with breast cancer. breast cancer Res Treat. 1991;18:189- 198.
19. Bergman L, Dakker G, van Leeuwen FE, Huisman SJ, van Dam FS, van Dongen JA. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer. 1991;67:2227-2234.
20. Bergman L, Kluck HM, van Leeuwen FE, et al. The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: a population-based study. Eur J Cancer. 1992:1475- 1480.
21. Sant M, Gatta G, Micheli A, et al. Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer. 1991;27:981-984.
22. Levi F, Randimbison L, La Vecchia C. breast cancer survival in relation to sex and age. Oncology. 1992;49:413- 417.
23. La Rosa F, Patavino VM, Epifani AC, Petrinelli AM, Minelli L, Mastrandrea V. Ten-year survival and age at diagnosis of women with breast cancer from a population-based study in Umbria, Italy. Tumori. 1996;82:441-443.
24. Busch E, Kemeny M, Fremgen A, Osteen RT, Winchester DP, Clive RE. Patterns of breast cancer care in the elderly. Cancer. 1996;78:101-111.
25. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer. 1997;33:425-428.
26. Sant M, Capocaccia R, Verdecchia A, et al. Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. The EUROCARE Working Group. Int J Cancer. 1998;77:679-683.
27. Lethaby AE, Mason BH, Holdaway IM, Kay RG. Age and ethnicity as prognostic factors influencing overall survival in breast cancer patients in the Auckland region. Auckland breast cancer Study Group [published erratum appears in N Z Med J.1993;106(954):166]. N Z Med J. 1992;105:485-488.
28. Thurfjell EL, Lindgren JA. breast cancer survival rates with mammographic screening: similar favorable survival rates for women younger and those older than 50 years [see comments]. Radiology. 1996;201:421-426.
29. Ezzat A, Raja MA, Zwaan F, Brigden M, Rostom A, Bazarbashi S. The lack of age as a significant prognostic factor in non-metastatic breast cancer. Eur J Surg Oncol. 1998;24:23-27.
30. Masetti R, Antinori A, Terribile D, et al. breast cancer in women 70 years of age or older. J Am Geriatr Soc. 1996;44:390-393.
31. Barchielli A, Balzi D. Age at diagnosis, extent of disease and breast cancer survival: a population-based study in Florence, Italy. Tumori. 2000;86:119-123.
32. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually [see comments]. J Natl Cancer Inst. 1989;81:1879-1886.
33. Steinberg K, Thacker S, Smith S, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-1990.
34. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues- Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992;79:286-294.
35. Collaborative Group on Hormonal Factors in breast cancer. breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047- 1059.
36. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485-491.
37. Ross R, Paganini-Hill A, Wan P, Pike M. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;16:328- 332.
38. Thomas HV, Reeves GK, Key TJA. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control. 1997;8.
39. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292- 1299.
40. Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med. 1999;130:270-277.
41. Garfinkel L, Bofetta P, Stellman S. Alcohol and breast cancer: a cohort study. Prev Med. 1988;17:686-693.
42. Gapstur S, Potter J, Sellers T, et al. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol. 1992;136:1221-1231.
43. Longnecker MP. A meta-analysis of alcohol consumption in relation to breast cancer risk. JAMA. 1994;260:73- 82.
44. Freudenheim JL, Marshall JR, Vena JE, et al. Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. J Natl Cancer Inst. 1996;88:340-348.
45. Fund AIfCR-WCR. Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC; American Institute for Cancer Research; 1997.
46. Willett W, Stampfer M, Colditz G. Dietary fat and risk of breast cancer. N Engl J Med. 1987;316:22-28.
47. Hunter D, Spiegelman D, Adami H, et al. Cohort studies of fat intake and the risk of breast cancer—a pooled analysis. N Engl J Med. 1996;334:356-361.
48. Holmes MD, Hunter DJ, Colditz GA, et al. Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA. 1999;281:914-920.
49. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278:1407-1411.
50. Le Marchand L, Kolonel LN, Earle ME, Mi MP. Body size at different periods of life and breast cancer risk. Am J Epidemiol. 1988;128:137-152.
51. Ziegler RG, Hoover RN, Nomura AMY, et al. Relative weight, weight change, height, and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1996;88:650- 660.
52. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med. 1997;336:1269- 1275.
53. Rockhill B, Willett WC, Hunter DJ, et al. A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med. 1999;159:2290- 2296.
54. Levi F, Pasche C, Lucchini F, La Vecchia C. Occupational and leisure time physical activity and the risk of breast cancer. Eur J Cancer. 1999;35:775-778.
55. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991;48:232-242.
56. Easton DF, Ford D, Bishop DT, and the breast cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet. 1995;56:265-271.
57. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA. 1997;277:997-1003.
58. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
59. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998;352:1337-1339.
60. Issacs CJD, Peshkin BN, Lerman C. Evaluation and management of women with a strong family history of breast cancer. In: Harris JR, ed. Diseases of the Breast. Philadelphia; Lippincott Williams & Wilkins; 2000.
61. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women [see comments]. J Clin Oncol. 1998;16:1642-1649.
62. Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999;91:2112-2117.
63. Robson M. Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. J Clin Oncol. 2000;18:113S-118S.
64. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000;18:3360-3369.
65. Chappuis PO, Kapusta L, Begin LR, et al. Germline BRCA1/2 mutations and p27 (Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000;18:4045-4052.
66. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol. 2000;18:4053- 4059.
67. Offit K, Brown K. Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol. 1994;12:1724-1736.
68. Stewart JA, Foster RS. breast cancer and aging. Semin Oncol. 1989;16:41-50.
69. Satariano WA, Belle SH, Swanson GM. Severity of breast cancer at diagnosis: a comparison of age and extent of disease in black and white women. Am J Public Health. 1986;76:779-782.
70. Golledge J, Wiggins JE, Callam MJ. Age-related variation in the treatment and outcomes of patients with breast carcinoma. Cancer. 2000;88:369-374.
71. Dawson DA, Thompson GB. breast cancer Risks Factors and Screening: United States, 1987. Series 10: Data from the National Health Interview Survey, No 172. Dept. of Health and Human Services pub 90-1550. Hyattsville, MD; National Center for Health Statistics; 1990.
72. Samet JM, Hunt WC, Lerchen ML, et al. Delay in seeking care for cancer symptoms: a population-based study of elderly New Mexicans. J Natl Cancer Inst. 1988;80:432- 438.
73. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
74. McCarty KS, Silva JS, Cox EB, Leight GS, Wells SA. Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg. 1983;197:123-127.
75. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984;2:1102-1109.
76. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550-556.
77. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastatic and poor long-term survival in breast cancer. Int J Cancer. 1991;49:650-655.
78. Gentili C, Sanfilippo O, Silvestrini R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer. 1981;48:974-979.
79. Owens MA, Beardslee S, Wenger CR, et al. DNA ploidy and S-phase fraction by flow cytometry in a large breast cancer data base. Proc Am Assoc Cancer Res. 1990;31:184.
80. Lyman GH, Lyman S, Balducci L, et al. Age and the risk of breast cancer recurrence. Cancer Control. 1996;3:421- 427.
81. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS. Histopathology of breast cancer in relation to age. Br J Cancer. 1997;75:593-596.
82. Schaefer G, Rosen PP, Lesser ML, et al. Breast carcinoma in the elderly woman: pathology prognosis, and survival. Pathol Annu. 1984;19:195-219.
83. Schwab R, Walters CA, Weksler ME. Host defense mechanisms and aging. Semin Oncol. 1989;16:20-27.
84. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77-84.
85. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336:1465-1471.
86. Fisher B, Costantino JP, Wickerham DL, Redmond CK, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371- 1388.
87. Gail MH, Costantino JP, Bryant J, Croyle R, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829- 1846.
88. Kelloff GJ, Lubet RA, Lieberman R, et al. Aromatase inhibitors as potential cancer chemopreventive. Cancer Epidemiol Biomarkers Prev. 1998;7:65-78.
89. Jordan VC. Estrogen receptor as a target for the prevention of breast cancer. J Lab Clin Med. 1999;133:408- 414.
90. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res. 2000;78:199-334.
91. Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci. 1995;761:355-360.
92. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women—results from the MORE randomized trial. JAMA. 1999;281:2189-2197.
93. Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging. 1999;14:323- 336.
94. Fish EB, Chapman JA, Link MA. Competing causes of death for primary breast cancer. Ann Surg Oncol. 1998;5:368-375.
95. US Department of Health and Human Services. Health United States 1996-7 and injury chartbook; 1997. DHHS Publication No. 97-1232. National Center for Health Statistics. Hyattsville, Maryland: 1997.
96. Mueller CB, Ames F, Anderson GD. breast cancer in 3558 women: age as a significant determinant in the rate of dying and causes of death. Surgery. 1978;83:123-132.
97. Manton KG, Wrigley JM, Cohen HJ, et al. Cancer mortality, aging, and patterns of comorbidity in the United States: 1968 to 1986. J Gerontol. 1991;46(4):S225-S234.
98. Santoriano WA, Ragheb NE, Dupuis MA. Comorbidity in older women with breast cancer: an epidemiologic approach. In: Yancik R, Yates J, eds. Cancer in the Elderly: Approaches to Elderly Detection and Treatment. New York: Springer; 1989:71.
99. Satariano WA. Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. J Gerontol. 1992;47:24-31.
100. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104-110.
101. Kimmick GG, Muss HB. breast cancer in special populations. In: Harris JR, ed. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2000:945-954.
102. Winchester DJ, Menck HR, Winchester DP. National treatment trends for ductal carcinoma in situ of the breast. Arch Surg.1997;132:660-665.
103. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913-918.
104. Silverstein MJ, Gamagami P, Colburn WJ. Coordinated biopsy team: surgical, pathologic and radiologic issues. In: Silverstein MJ, ed. Ductal Carcinoma In Situ of the Breast. Baltimore: Williams & Wilkins; 1997:333-342.
105. Morrow M, Schnitt SJ, Harris JR. Ductal carcinoma in situ and microinvasive disease. In: Harris JR, ed. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2000:383-401.
106. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441-452.
107. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 1999;353:1993-2000.
108. Van Zee KJ, Liberman L, Samli B, Tran KN, et al. Long-term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999;86:1757-1767.
109. Vincini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18:296-306.
110. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast [see comments]. N Engl J Med. 1999;340:1455-1461.
111. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305:6-11.
112. Sarrazin D, Le M, Rouesse J, et al. Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less. The experience of the Institut Gustave-Roussy. Cancer. 1984;53:1209- 1213.
113. Veronesi U, Banfi A, Del Vecchio M, et al. Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer. Eur J Cancer Clin Oncol. 1986;22:1085-1089.
114. Fisher B, Redmond C, Poisson R, et al. Eight year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320:822-828.
115. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991;265:391-395.
116. NIH Consensus Conference Statement on Adjuvant Therapy for breast cancer. From the NIH Consensus Development Conference on Adjuvant Therapy for breast cancer. Bethesda, MD; National Institutes of Health; 2000.
117. Merchant TE, McCormick B, Yahalom J, Borgen P. The influence of older age on breast cancer treatment decisions and outcome [see comments]. Int J Radiat Oncol Biol Phys. 1996;34:565-570.
118. Hunt KE, Fry DE, Bland KI. Breast carcinoma in the elderly patient: an assessment of operative risk, morbidity and mortality. Am J Surg. 1980;140:339-342.
119. Amsterdam E, Birkenfeld S, Gilad A, et al. Surgery for carcinoma of the breast in women over 70 years of age. J Surg Oncol. 1987;35:180-183.
120. Svastics E, Sulyok Z, Besznyak I. Treatment of breast cancer in women older than 70 years. J Surg Oncol. 1989;41:19-21.
121. Schain W, Edwards BK, Gorrell CR, et al. Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs. excisional biopsy and irradiation. breast cancer Res Treat. 1983;3:377-382.
122. de Haes JC, van Oostrom MA, Welvaart K. The effect of radical and conserving surgery on the quality of life of early breast cancer patients. Eur J Surg Oncol. 1986;12:337-342.
123. Lasry JC, Margolese RG, Poisson R, et al. Depression and body image following mastectomy and lumpectomy. J Chron Dis. 1987;40:529-534.
124. Kemeny MM, Wellisch DK, Schain WS. Psychosocial outcome in a randomized surgical trial for treatment of primary breast cancer. Cancer. 1988;62:1231-1237.
125. Sandison AJ, Gold DM, Wright P, Jones PA. Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Br J Surg. 1996;83:994-996.
126. Martelli G, De Palo G. breast cancer in elderly women (> or = 70 years): which treatment? Tumori. 1999;85:421-424.
127. Vinokur AD, Threatt BA, Vinokur-Kaplan, et al. The process of recovery from breast cancer for younger and older patients: changes during the first year. Cancer. 1990;65:1242-1254.
128. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast [see comments]. N Engl J Med. 1993;328:1587-1591.
129. Nemoto T, Patel JK, Rosner D, et al. Factors affecting recurrence in lumpectomy without irradiation for breast cancer. Cancer. 1991;67:2079-2082.
130. Reed MW, Morrison JM. Wide local excision as the sole primary treatment in elderly patients with carcinoma of the breast. Br J Surg. 1989;76:898-900.
131. Kantorowitz DA, Poulter CA, Sischy B, et al. Treatment of breast cancer among elderly women with segmental mastectomy or segmental mastectomy plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1988;15:263- 270.
132. De Csepel J, Tartter PI, Gajdos C. When not to give radiation therapy after breast-conserving surgery for breast cancer. J Surg Oncol. 2000;74:273-277.
133. Wyckoff J, Greenberg H, Sanderson R, et al. Breast irradiation in the older woman: a toxicity study. J Am Geriatr Soc. 1994;42:150-152.
134. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674-681.
135. Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg. 1986;73:580-584.
136. Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992;66:136-138.
137. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345-2350.
138. Pezner RD, Patterson MP, Hill LR, et al. Arm lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys. 1986;12:2079-2083.
139. Delouche G, Bachelot F, Premont M, Kurtz JM. Conservation treatment of early breast cancer: long term results and complications. Int J Radiat Oncol Biol Phys. 1987;13:29-34.
140. Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer. 1998;83:1362-1368.
141. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study [see comments]. N Engl J Med. 1998;339:941-946.
142. Hsueh EC, Hansen N, Giuliano AE. Intraoperative lymphatic mapping and sentinel lymph node dissection in breast cancer. CA Cancer J Clin. 2000;50:279-291.
143. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer [see comments]. Ann Surg. 1994;220:391- 398: discussion 398-401.
144. Morrow M, Harris JR. Primary treatment of invasive breast cancer. In: Harris JR, ed. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2000: 515-560.
145. DiFronzo LA, Hansen NM, Stern SL, Brennan MB, Giuliano AE. Does sentinel lymphadenectomy improve staging and alter therapy in elderly women with breast cancer?Ann Surg Oncol. 2000;7:406-410.
146. Wazer DE, Erban JK, Robert NJ, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer. 1994;74:878- 883.
147. Feigelson BJ, Acosta JA, Feigelson HS, Findley A, Saunders EL. T1 breast carcinoma in women 70 years of age and older may not require axillary node dissection. Am J Surg. 1996;172:487-490.
148. Naslund E, Fernstad R, Ekman S, et al. breast cancer in women over 75 years: is axillary dissection always necessary?Eur J Surg. 1996;162:867-871.
149. Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early stage breast carcinoma. J Clin Oncol. 1991;74:878-883.
150. Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982;284:869-870.
151. Bradbeer JW, Kyngdon J. Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol. 1983;9:31-34.
152. Allan SG, Rodger A, Smyth JF, Leonard RC, Chetty U, Forrest AP. Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed). 1985;290:358.
153. Bates T, Riley DL, Houghton J, Fallowfield L, Baum M. breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly breast cancer Working Party. Br J Surg. 1991;78:591-594.
154. Robertson JF, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. Br Med J. 1988;297:511-514.
155. Gazet JC, Markopoulos C, Ford HT, Coombes RC, Bland JM, Dixon RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988;1:679-681.
156. Margolese RG, Foster RS Jr. Tamoxifen as an alternative to surgical resection for selected geriatric patients with primary breast cancer. Arch Surg. 1989;124:548-550: discussion 550-551.
157. Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78:213-217.
158. Akhtar SS, Allan SG, Rodger A, Chetty UD, Smyth JF, Leonard RC. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol. 1991;17:30-35.
159. Ciatto S, Bartoli D, Iossa A, Grazzini G, Cirillo A. Response of primary breast cancer to tamoxifen alone in elderly women. Tumori. 1991;77:328-330.
160. Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs. surgery in elderly patients with breast cancer. Eur J Surg Oncol. 1994;20:207-214.
161. Mustacchi G, Milani S, Pluchinotta A, De Matteis A, Rubagotti A, Perrota A. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trail. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res. 1994;14:2197-2200.
162. Ciatto S, Cirillo A, Confortini M, Cardillo CL. Tamoxifen as primary treatment of breast cancer in elderly patients. Neoplasma. 1996;43:43-45.
163. Rostom AY, Pradhan DG, White WF. Once weekly irradiation in breast cancer. Int J Radiat Oncol Biol Phys. 1987;13:551-555.
164. Maher M, Campana F, Mosseri V, et al. breast cancer in elderly women: a retrospective analysis of combined treatment with tamoxifen and once-weekly irradiation [see comments]. Int J Radiat Oncol Biol Phys. 1995;31:783-789.
165. Early breast cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1467.
166. Early breast cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
167. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol. 1989;7:803-815.
168. Jordan VC. Estrogen-receptor mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst. 1990;82:1662-1663.
169. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990;50:4177-4189.
170. Swedish breast cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. [see comments]. J Natl Cancer Inst. 1996;88:1543-1549.
171. Current Trials Working Party of the Cancer Research Campaign breast cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen during in women aged fifty years or older with breast cancer. [see comments] [published erratum appears in J Natl Cancer Inst. 1997;89(8):590]. J Natl Cancer Inst. 1996;88:1834-1849.
172. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [see comments]. J Natl Cancer Inst. 1996;88:1529-1542.
173. Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer. 1996;74:297-299.
174. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group [see comments]. J Natl Cancer Inst. 1996;88:1828-1833.
175. Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International breast cancer Study Group. J Clin Oncol. 1990;8:519-526.
176. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death [see comments]. J Clin Oncol. 1993;11:29-35.
177. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484.
178. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842- 1847.
179. McCarthy NJ, Swain SM. Update on adjuvant chemotherapy for early breast cancer. Oncology. 2000;14:1267-1280.
180. Anonymous. Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer Trialists' Collaborative Group [see comments]. Lancet. 1998;351:1451-1467.
181. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16 [see comments]. J Clin Oncol.1990;8:1005-1018.
182. Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy or endocrine therapy alone in postmenopausal patients: Ludwig studies III and IV. In: Senn H, Goldhirsch A, Gelber RD, et al. eds. Recent Results in Cancer Research: Adjuvant Therapy of Primary breast cancer. Berlin: Springer-Verlag; 1989:153-162.
183. Winer E, Partridge AH, Burstein HJ. Influences of treatment-related side effects and quality-of-life issues on individual decision-making about adjuvant therapy: chemotherapy and combined chemohormonal therapy. NIH Consensus Development Conference on Adjuvant Therapy for breast cancer. Bethesda, MD; National Institutes of Heath; 2000.
184. Menard S, Tagliabue E, Campiglio M, et al. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000;182:150-162.
185. Tripathy D. Overview of recent clinical studies of trastuzumab alone or in combination with chemotherapy. Biol Ther breast cancer. 2000;2:2-8.
186. Hudis C, Seidman A, Paton V, et al. Characterization of cardiac dysfunction in the Herceptin (traztuzumab) clinical trials. breast cancer Res Treat. 1998;50:12a [abstract 24].
187. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International breast cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412-1422.
188. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer. 1983;52:1986-1992.
189. Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994;12:2447-2452.
190. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Investig. 2000;18:521-529.
191. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary breast cancer [see comments]. J Natl Cancer Inst. 1998;90:1601-1608.
192. Extermann M, Balducci GH, Lyman H. What threshold for adjuvant therapy in older breast cancer patients?Proc Am Soc Clin Oncol. 1998;17:102a.
193. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987;317:1490-1495.
194. Tannock IF, Boyd NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer [see comments]. J Clin Oncol. 1988;6:1377-1387.
195. Baum M, Priestman T, West RR, et al. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. In: Mouridsen H, Palshof T, eds. breast cancer: Experimental and Clinical Aspects. Oxford: Pergamon Press; 1980:223.
196. Buzdar A, Nabholtz JM, Robertson JF, et al. Anastrozole (Arimidex®) versus tamoxifen as first-line therapy for advanced breast cancer (abc) in postmenopausal (pm) women: combined analysis from two identically designed multicenter trials. Proc Am Soc Clin Oncol. 2000;19:154a [abstract 609d].
197. Smith R, Sun Y, Garin A, et al. Femara® (letrozole) showed significant improvement in efficacy over tamoxifen as first-line treatment in postmenopausal women with advanced breast cancer. breast cancer Res Treat. 2000;64:27 [abstract 8].
198. Taylor SGT, Gelman RS, Falkson G, Cummings FJ. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med. 1986;104:455-461.
199. Rose C, Kamby C, Mouridsen HT, Andersson M, et al. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. breast cancer Res Treat. 2000;61:103-110.
200. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA. 1992;268:57-62.
201. Chlebowski RT, Smalley RV, Weiner JM, Irwin LE, Bartolucci AA, Bateman JR. Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group. Br J Cancer. 1989;59:227-230.
202. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 1998;16:3720-3730.
203. Muss HB, Case LD, Richards Fd, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association [see comments]. N Engl J Med. 1991;325:1342-1348.
204. Gelman RS, Taylor SGT. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984;2:1404-1413.
205. Kimmick GG, Fleming R, Muss HB, Balducci L. Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging. 1997;10:34-49.
206. Bajetta E, Biganzoli L, Carnaghi C, et al. Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. Cancer. 1998;83:1136-1141.
207. Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999;10:397-402.
208. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia breast cancer Study Group [see comments]. N Engl J Med. 1996;335:1785-1791.
209. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
210. Hillner BE. The role of bisphosphonates in metastatic breast cancer. Semin Radiat Oncol. 2000;10:250-253.
211. Ganz PA, Schag CC, Heinzich RL. The psychosocial impact of cancer on the elderly. A comparison with younger patients. J Am Geriatr Soc. 1985;33:429-435.
212. Ganz PA. breast cancer in older women: quality-of-life considerations. Cancer Control. 1994;1:372-379.
213. Compas BE, Stoll MF, Thomsen AH, Oppedisano G, Epping-Jordan JE, Krag DN. Adjustment to breast cancer: age-related differences in coping and emotional distress. breast cancer Res Treat. 1999;54:195-203.
214. Wenzel LB, Fairclough DL, Brady MJ, et al. Age- related differences in the quality of life of breast carcinoma patients after treatment. Cancer. 1999;86:1768-1774.
215. Kantor DE, Houldin A. breast cancer in older women: treatment, psychosocial effects, interventions, and outcomes. J Gerontol Nurs. 1999;25:19-25: quiz 54-55.
216. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA. 1987;257:2766-2770.
217. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385-3390.
218. Chu J, Diehr P, Feigl P, et al. The effect of age on the care of women with breast cancer in community hospitals. J Gerontol. 1987;42:185-190.
219. Silliman RA, Guadagnoli E, Weitberg AB, Mor V. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989;44:M46-M50.
220. Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer [see comments]. N Engl J Med. 1992;326:1097-1101.
221. Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer [see comments]. N Engl J Med. 1992;326:1102-1107.
222. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993;85:1580- 1584.
223. Samet JM, Hunt WC, Farrow DC. Determinants of receiving breast-conserving surgery. The Surveillance, Epidemiology, and End Results Program, 1983-1986. Cancer. 1994;73:2344-2351.
224. Du X, Freeman JL, Freeman DH, Syblik DA, Goodwin JS. Temporal and regional variation in the use of breast- conserving surgery and radiotherapy for older women with early-stage breast cancer from 1983 to 1995. J Gerontol A Biol Sci Med Sci. 1999;54:M474-M478.
225. Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer. 2000;89:561-573.
226. Lash TL, Silliman RA, Guadagnoli E, Mor V. The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer. 2000;89:1739-1747.
227. Mor V, Masterson-Allen S, Goldberg RJ, Cummings FJ, Glicksman AS, Fretwell MD. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc. 1985;33:585-589.
228. Fetting JH, Comstock GW, Eby S, et al. The effect of aging on the utilization of chemotherapy for metastatic breast cancer: a population-based study. Cancer Investig. 1997;15:199-203.
229. Goodwin JS, Samet JM. Care received by older women diagnosed with breast cancer. Cancer Control. 1994;1:313-319.
230. Benson ABD, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study [see comments]. J Clin Oncol. 1991;19:2067-2075.
231. Kemeny M, Muss HB, Kornblith AB, Peterson B, Wheeler J, Cohen HJ. Barriers to participation of older women with breast cancer in clinical trials. Proc Am Soc Clin Oncol. 2000;19:602a (abstract 2371).
232. American Joint Committee on Cancer. In: Beahrs OH HD, Hutter RVP, et al., eds. Manual for Staging of Cancer, 4th Ed. Philadelphia: Lippincott; 1992:149-154.
233. Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975;140:528-534.
234. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978;41:1170-1178.
